An Apoferritin-based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

Anchala I Kuruppu; Lei Zhang; Hilary Collins; Lyudmila Turyanska; Neil R Thomas; Tracey D Bradshaw

doi:10.1002/adhm.201500389

An Apoferritin-based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

Adv Healthc Mater. 2015 Dec 30;4(18):2816-21. doi: 10.1002/adhm.201500389. Epub 2015 Nov 23.

Authors

Anchala I Kuruppu¹, Lei Zhang², Hilary Collins¹, Lyudmila Turyanska³, Neil R Thomas², Tracey D Bradshaw¹

Affiliations

¹ Centre for Biomolecular Sciences, School of Pharmacy, The University of Nottingham, Nottingham, NG7 2RD, UK.
² Centre for Biomolecular Sciences, School of Chemistry, The University of Nottingham, Nottingham, NG7 2RD, UK.
³ School of Physics and Astronomy, The University of Nottingham, Nottingham, NG7 2RD, UK.

PMID: 26592186
DOI: 10.1002/adhm.201500389

Abstract

Anticancer drug Gefitinib encapsulated within human heavy chain apoferritin by diffusion allows pH-controlled sustained release of cargo. The combination of increased cellular uptake, and potent and enhanced antitumor activity against the HER2 overexpressing SKBR3 cell line compared to Gefitinib alone, makes it a promising carrier for delivery of drugs to tumor sites.

Keywords: Gefitinib; apoferritin; breast cancer; drug delivery; nanoparticles.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Apoferritins / metabolism*
Cell Line, Tumor
Drug Delivery Systems / methods*
Endocytosis / drug effects
Gefitinib
Humans
Protein Kinase Inhibitors / pharmacology*
Quinazolines / pharmacology*

Substances

Protein Kinase Inhibitors
Quinazolines
Apoferritins
Gefitinib

Abstract

Publication types

MeSH terms

Substances

Grants and funding